Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.

Hohlbaum AM, Gille H, Trentmann S, Kolodziejczyk M, Rattenstetter B, Laarakkers CM, Katzmann G, Christian HJ, Andersen N, Allersdorfer A, Olwill SA, Meibohm B, Audoly LP, Swinkels DW, van Swelm RPL.

Br J Pharmacol. 2018 Apr;175(7):1054-1065. doi: 10.1111/bph.14143. Epub 2018 Feb 23.

2.

A novel psychoanalytical approach: An electrochemical ligand-binding assay to screen antipsychotics.

Kilic T, Brunner V, Audoly L, Carrara S.

Biosens Bioelectron. 2018 Feb 15;100:139-147. doi: 10.1016/j.bios.2017.08.059. Epub 2017 Aug 30.

PMID:
28886458
3.

Actinic keratosis modelling in mice: A translational study.

Pillon A, Gomes B, Vandenberghe I, Cartron V, Cèbe P, Blanchet JC, Sibaud V, Guilbaud N, Audoly L, Lamant L, Kruczynski A.

PLoS One. 2017 Jun 29;12(6):e0179991. doi: 10.1371/journal.pone.0179991. eCollection 2017.

4.

Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class.

Gille H, Hülsmeyer M, Trentmann S, Matschiner G, Christian HJ, Meyer T, Amirkhosravi A, Audoly LP, Hohlbaum AM, Skerra A.

Angiogenesis. 2016 Jan;19(1):79-94. doi: 10.1007/s10456-015-9490-5. Epub 2015 Dec 9.

PMID:
26650228
5.

In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.

Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA.

J Nucl Med. 2014 Apr;55(4):665-71. doi: 10.2967/jnumed.113.124941. Epub 2014 Mar 10.

6.

First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.

Mross K, Richly H, Fischer R, Scharr D, Büchert M, Stern A, Gille H, Audoly LP, Scheulen ME.

PLoS One. 2013 Dec 13;8(12):e83232. doi: 10.1371/journal.pone.0083232. eCollection 2013.

7.

A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.

Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, Lunde BM, Jaworski J, Burrows JF, Chiriaco C, Christian HJ, Hülsmeyer M, Trentmann S, Jensen K, Hohlbaum AM, Audoly L.

Mol Cancer Ther. 2013 Nov;12(11):2459-71. doi: 10.1158/1535-7163.MCT-13-0318. Epub 2013 Sep 3.

8.

A novel role of prostaglandin E2 in neuropathic pain: blockade of microglial migration in the spinal cord.

Kunori S, Matsumura S, Okuda-Ashitaka E, Katano T, Audoly LP, Urade Y, Ito S.

Glia. 2011 Feb;59(2):208-18. doi: 10.1002/glia.21090.

PMID:
21125641
9.

Distinct expression profiles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies.

Li Y, Burns JA, Cheney CA, Zhang N, Vitelli S, Wang F, Bett A, Chastain M, Audoly LP, Zhang ZQ.

Biologics. 2010 Jun 24;4:163-71.

10.

Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.

Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, Huang L, Vitelli S, Vo KT, Haytko P, Zhao JZ, Baleydier F, L'Heureux S, Wang H, Gordon WR, Thoryk E, Andrawes MB, Tiyanont K, Stegmaier K, Roti G, Ross KN, Franlin LL, Wang H, Wang F, Chastain M, Bett AJ, Audoly LP, Aster JC, Blacklow SC, Huber HE.

PLoS One. 2010 Feb 8;5(2):e9094. doi: 10.1371/journal.pone.0009094.

11.

Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.

Oflazoglu E, Audoly LP.

MAbs. 2010 Jan-Feb;2(1):14-9. Epub 2010 Jan 30. Review.

12.

The impact of microsomal prostaglandin e synthase 1 on blood pressure is determined by genetic background.

Facemire CS, Griffiths R, Audoly LP, Koller BH, Coffman TM.

Hypertension. 2010 Feb;55(2):531-8. doi: 10.1161/HYPERTENSIONAHA.109.145631. Epub 2010 Jan 11.

13.

Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis.

Jania LA, Chandrasekharan S, Backlund MG, Foley NA, Snouwaert J, Wang IM, Clark P, Audoly LP, Koller BH.

Prostaglandins Other Lipid Mediat. 2009 Apr;88(3-4):73-81. doi: 10.1016/j.prostaglandins.2008.10.003. Epub 2008 Nov 1.

14.

MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.

Xu D, Rowland SE, Clark P, Giroux A, Côté B, Guiral S, Salem M, Ducharme Y, Friesen RW, Méthot N, Mancini J, Audoly L, Riendeau D.

J Pharmacol Exp Ther. 2008 Sep;326(3):754-63. doi: 10.1124/jpet.108.138776. Epub 2008 Jun 4.

PMID:
18524979
15.

Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-alpha.

Chen B, Zong Q, Cibotti R, Morris C, Castaneda J, Naiman B, Liu D, Glodek A, Sims GP, Herbst R, Horrigan SK, Kiener PA, Soppet D, Coyle AJ, Audoly L.

Mol Med. 2008 Jul-Aug;14(7-8):374-82. doi: 10.2119/2008-00028.Chen.

16.

Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis.

Chen M, Boilard E, Nigrovic PA, Clark P, Xu D, Fitzgerald GA, Audoly LP, Lee DM.

Arthritis Rheum. 2008 May;58(5):1354-65. doi: 10.1002/art.23453.

17.

Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction.

Degousee N, Fazel S, Angoulvant D, Stefanski E, Pawelzik SC, Korotkova M, Arab S, Liu P, Lindsay TF, Zhuo S, Butany J, Li RK, Audoly L, Schmidt R, Angioni C, Geisslinger G, Jakobsson PJ, Rubin BB.

Circulation. 2008 Apr 1;117(13):1701-10. doi: 10.1161/CIRCULATIONAHA.107.749739. Epub 2008 Mar 17.

PMID:
18347209
18.

MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.

Clark P, Rowland SE, Denis D, Mathieu MC, Stocco R, Poirier H, Burch J, Han Y, Audoly L, Therien AG, Xu D.

J Pharmacol Exp Ther. 2008 May;325(2):425-34. doi: 10.1124/jpet.107.134510. Epub 2008 Feb 20.

PMID:
18287210
19.

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.

Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P.

Arthritis Res Ther. 2008;10(1):R14. doi: 10.1186/ar2365. Epub 2008 Jan 30.

20.

Role of microsomal prostaglandin E synthase 1 in the kidney.

Francois H, Facemire C, Kumar A, Audoly L, Koller B, Coffman T.

J Am Soc Nephrol. 2007 May;18(5):1466-75. Epub 2007 Apr 18.

21.

Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.

Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ.

Nat Immunol. 2007 May;8(5):487-96. Epub 2007 Apr 8. Erratum in: Nat Immunol. 2007 Jul;8(7):780.

PMID:
17417641
22.

Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species.

Rowland SE, Clark P, Gordon R, Mullen AK, Guay J, Dufresne L, Brideau C, Cote B, Ducharme Y, Mancini J, Chan CC, Audoly L, Xu D.

Eur J Pharmacol. 2007 Apr 10;560(2-3):216-24. Epub 2007 Jan 20.

PMID:
17316604
23.

Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis.

Pulichino AM, Rowland S, Wu T, Clark P, Xu D, Mathieu MC, Riendeau D, Audoly LP.

J Pharmacol Exp Ther. 2006 Dec;319(3):1043-50. Epub 2006 Sep 14.

PMID:
16973887
24.

Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.

McClure KF, Letavic MA, Kalgutkar AS, Gabel CA, Audoly L, Barberia JT, Braganza JF, Carter D, Carty TJ, Cortina SR, Dombroski MA, Donahue KM, Elliott NC, Gibbons CP, Jordan CK, Kuperman AV, Labasi JM, Laliberte RE, McCoy JM, Naiman BM, Nelson KL, Nguyen HT, Peese KM, Sweeney FJ, Taylor TJ, Trebino CE, Abramov YA, Laird ER, Volberg WA, Zhou J, Bach J, Lombardo F.

Bioorg Med Chem Lett. 2006 Aug 15;16(16):4339-44. Epub 2006 Jun 12.

PMID:
16759861
25.

c-Jun N-terminal kinase-mediated stabilization of microsomal prostaglandin E2 synthase-1 mRNA regulates delayed microsomal prostaglandin E2 synthase-1 expression and prostaglandin E2 biosynthesis by cardiomyocytes.

Degousee N, Angoulvant D, Fazel S, Stefanski E, Saha S, Iliescu K, Lindsay TF, Fish JE, Marsden PA, Li RK, Audoly LP, Jakobsson PJ, Rubin BB.

J Biol Chem. 2006 Jun 16;281(24):16443-52. Epub 2006 Apr 19.

26.

Neutrophil-derived leukotriene B4 is required for inflammatory arthritis.

Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, Austen KF, Lee DM.

J Exp Med. 2006 Apr 17;203(4):837-42. Epub 2006 Mar 27.

27.

COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis.

Lovgren AK, Jania LA, Hartney JM, Parsons KK, Audoly LP, Fitzgerald GA, Tilley SL, Koller BH.

Am J Physiol Lung Cell Mol Physiol. 2006 Aug;291(2):L144-56. Epub 2006 Feb 10.

28.

Coupling of COX-1 to mPGES1 for prostaglandin E2 biosynthesis in the murine mammary gland.

Chandrasekharan S, Foley NA, Jania L, Clark P, Audoly LP, Koller BH.

J Lipid Res. 2005 Dec;46(12):2636-48. Epub 2005 Oct 3.

29.

Prostaglandin E2 protects lower airways against bronchoconstriction.

Hartney JM, Coggins KG, Tilley SL, Jania LA, Lovgren AK, Audoly LP, Koller BH.

Am J Physiol Lung Cell Mol Physiol. 2006 Jan;290(1):L105-13. Epub 2005 Aug 19.

30.

Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages.

Trebino CE, Eskra JD, Wachtmann TS, Perez JR, Carty TJ, Audoly LP.

J Biol Chem. 2005 Apr 29;280(17):16579-85. Epub 2005 Feb 18.

31.

Exploring type I angiotensin (AT1) receptor functions through gene targeting.

Crowley SD, Tharaux PL, Audoly LP, Coffman TM.

Acta Physiol Scand. 2004 Aug;181(4):561-70. Review.

PMID:
15283771
32.

Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium.

Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, Klareskog L, Ulfgren AK, Jakobsson PJ.

Arthritis Rheum. 2004 Jun;50(6):1774-80.

33.

Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis.

Engblom D, Saha S, Engström L, Westman M, Audoly LP, Jakobsson PJ, Blomqvist A.

Nat Neurosci. 2003 Nov;6(11):1137-8. Epub 2003 Oct 19.

34.

Inhibition of IL-1beta-dependent prostaglandin E2 release by antisense microsomal prostaglandin E synthase 1 oligonucleotides in A549 cells.

Sweeney FJ, Wachtmann TS, Eskra JD, Verdries KA, Lambalot RH, Carty TJ, Perez JR, Audoly LP.

Mol Cell Endocrinol. 2003 Jul 31;205(1-2):151-7.

PMID:
12890577
35.

Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase.

Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP.

Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9044-9. Epub 2003 Jun 30.

36.

Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption.

Ke HZ, Qi H, Weidema AF, Zhang Q, Panupinthu N, Crawford DT, Grasser WA, Paralkar VM, Li M, Audoly LP, Gabel CA, Jee WS, Dixon SJ, Sims SM, Thompson DD.

Mol Endocrinol. 2003 Jul;17(7):1356-67. Epub 2003 Apr 3.

PMID:
12677010
37.

Receptors and signaling mechanisms required for prostaglandin E2-mediated regulation of mast cell degranulation and IL-6 production.

Nguyen M, Solle M, Audoly LP, Tilley SL, Stock JL, McNeish JD, Coffman TM, Dombrowicz D, Koller BH.

J Immunol. 2002 Oct 15;169(8):4586-93.

38.

The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis.

McCoy JM, Wicks JR, Audoly LP.

J Clin Invest. 2002 Sep;110(5):651-8.

39.

Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response.

Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM, Brissette W, Wicks JR, Audoly L, Gabel CA.

J Immunol. 2002 Jun 15;168(12):6436-45.

40.

Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus.

Coggins KG, Latour A, Nguyen MS, Audoly L, Coffman TM, Koller BH.

Nat Med. 2002 Feb;8(2):91-2. No abstract available.

PMID:
11821873
41.

Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition.

Athirakul K, Kim HS, Audoly LP, Smithies O, Coffman TM.

Kidney Int. 2001 Dec;60(6):2324-9.

42.

Review: Gene targeting studies of angiotensin II type 1 (AT1) receptors.

Coffman TM, Audoly LP, Oliverio MI.

J Renin Angiotensin Aldosterone Syst. 2001 Mar;2(1_suppl):S10-S15. doi: 10.1177/14703203010020010201. No abstract available.

PMID:
28095241
43.

The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure.

Stock JL, Shinjo K, Burkhardt J, Roach M, Taniguchi K, Ishikawa T, Kim HS, Flannery PJ, Coffman TM, McNeish JD, Audoly LP.

J Clin Invest. 2001 Feb;107(3):325-31.

44.

Role of EP(2) and EP(3) PGE(2) receptors in control of murine renal hemodynamics.

Audoly LP, Ruan X, Wagner VA, Goulet JL, Tilley SL, Koller BH, Coffman TM, Arendshorst WJ.

Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H327-33.

45.

What can knockout mice contribute to an understanding of hypertension?

Audoly LP, Le TH, Coffman TM.

Curr Hypertens Rep. 2000 Apr;2(2):192-7. Review.

PMID:
10981148
46.

Insights into the functions of type 1 (AT1) angiotensin II receptors provided by gene targeting.

Audoly LP, Oliverio MI, Coffman TM.

Trends Endocrinol Metab. 2000 Sep;11(7):263-9. Review.

PMID:
10920382
47.

Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo.

Audoly LP, Rocca B, Fabre JE, Koller BH, Thomas D, Loeb AL, Coffman TM, FitzGerald GA.

Circulation. 2000 Jun 20;101(24):2833-40.

PMID:
10859290
48.

Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM.

J Clin Invest. 1999 Dec;104(12):1693-701.

49.

Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.

Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH.

Nat Med. 1999 Oct;5(10):1199-202.

PMID:
10502826
50.

Identification of specific EP receptors responsible for the hemodynamic effects of PGE2.

Audoly LP, Tilley SL, Goulet J, Key M, Nguyen M, Stock JL, McNeish JD, Koller BH, Coffman TM.

Am J Physiol. 1999 Sep;277(3):H924-30. doi: 10.1152/ajpheart.1999.277.3.H924.

PMID:
10484412

Supplemental Content

Loading ...
Support Center